Loading clinical trials...
Loading clinical trials...
The Effect of D-cycloserine on Fear Learning and Extinction
The present study investigates the effect of d-cycloserine on learning and unlearning of fear in healthy humans and its underlying effect on the amygdala. As a second objective, the effect of genotype on fear learning will be studied.
A growing body of evidence suggests that the extinction of fear is mediated by the N-methyl-D-aspartate (NMDA) receptor activity in the basolateral amygdala. Intra-amygdala infusions of antagonists of this glutamate receptor in small animals (eg: rats, mice) have demonstrated a blockage of fear acquisition and extinction. Agonists, on the other hand, facilitate conditioned fear extinction. The animal studies are all based on the simple fear learning paradigm of conditioning. However, it is not clear that human anxiety disorders are based on prior conditioning encounter. Therefore it is important to disentangle the effect of DCS on acquisition and extinction in the context of a simple learning paradigm, particular its effect on the human amygdala.
Age
18 - 40 years
Sex
ALL
Healthy Volunteers
Yes
Catholic University Leuven, Departement of Radiology
Leuven, Belgium
Last Updated
January 31, 2023
d-Cycloserine
DRUG
Lactose pill
DRUG
Saliva sample
GENETIC
Functional neuroimaging (fMRI)
OTHER
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
NCT07287306
NCT07047300
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06948942